<DOC>
	<DOCNO>NCT00269607</DOCNO>
	<brief_summary>The purpose clinical trial study efficacy safety naltrexone implant relapse prevention patient complete treatment opiate addiction inpatient ( similarly control ) setting . Participants naltrexone experimental group prematched pairwise fashion patient want naltrexone implant first six month end inpatient treatment , reiceive treatment usual ( TAU ) Norwegian healthcare system . The hypothesis quality life , depression , opioid use , significantly well naltrexone group compare non 6- , 12- , 18-month follow-up . We also hypothesize implant prevent death opioid overdose 6 month commence treatment .</brief_summary>
	<brief_title>Naltrexone Implants Relapse Prevention</brief_title>
	<detailed_description />
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>soon complete inpatient treatment opioid addiction live southern Norway psychosis / major depression , currently treat pregnancy liver enzyme : ASAT ALAT &gt; threefold upper boundary maintenance treatment methadone buprenorphine</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2005</verification_date>
	<keyword>Substance abuse</keyword>
	<keyword>Treatment</keyword>
	<keyword>Relapse prevention</keyword>
	<keyword>opioid antagonist</keyword>
</DOC>